

Approximate number of whole blood or plasmapheresis donations required to manufacture Australia's plasma-derived therapies¹

Product	Plasma required to make one batch (kg)	No. of whole blood donations/batch	No. of plasmapheresis donations/batch	No. of whole blood donations/vial	No. of plasmapheresis donations/vial	Yield (vials/kg starting plasma) ²	No. of vials /100kg plasma
INTRAGAM® P 12g in 200mL Human Normal Immunoglobulin	10,000	34,247	15,267	7.8	3.5	0.44	44
INTRAGAM® P 3g in 50mL Human Normal Immunoglobulin	10,000	34,247	15,267	1.9	0.9	1.77	177
ALBUMEX® 4 500mL Human Albumin	10,000	34,247	15,267	2.7	1.2	1.29	129
ALBUMEX® 4 50mL Human Albumin	10,000	34,247	15,267	0.3	0.1	11.24	1,124
ALBUMEX® 20 100mL Human Albumin	10,000	34,247	15,267	2.8	1.2	1.24	124
ALBUMEX® 20 10mL Human Albumin	10,000	34,247	15,267	0.3	0.1	11	1,100
MonoFIX®-VF 500IU Human Coagulation Factor IX	5,000	17,123	7,634	11.4	5.1	0.3	30
MonoFIX®-VF 1000IU Human Coagulation Factor IX	5,000	17,123	7,634	31.1	13.9	0.11	11
THROMBOTROL®-VF 1000IU Human Antithrombin III	1,250	4,281	1,908	20.1	9.0	0.17	17
PROTHROMBINEX®-VF 500IU Human Prothrombin Complex	2,500	8,562	3,817	9.5	4.2	0.36	36
BIOSTATE® 250IU Human Coagulation Factor VIII	15,000	51,370	22,901	6.8	3.1	0.5	50
BIOSTATE® 500IU Human Coagulation Factor VIII	15,000	51,370	22,901	13.7	6.1	0.25	25
Normal Immunoglobulin-VF 2mL Human Normal Immunoglobulin	2,500	8,562	3,817	0.4	0.2	9.55	955
Normal Immunoglobulin-VF 5mL Human Normal Immunoglobulin	2,500	8,562	3,817	0.7	0.3	4.96	496
Rh(D) Immunoglobulin-VF 250IU Human Anti-D Rh ₀ Immunoglobulin	420	1,438	641	0.0	0.01	105.4	10,540
Rh(D) Immunoglobulin-VF 625IU Human Anti-D Rh ₀ Immunoglobulin	420	1,438	641	0.1	0.04	43.05	4,305
Hepatitis B Immunoglobulin-VF 100IU Human Hepatitis B Immunoglobulin	420	1,438	641	0.2	0.1	18.9	1,890
Hepatitis B Immunoglobulin-VF 400IU Human Hepatitis B Immunoglobulin	420	1,438	641	0.4	0.16	9.76	976
Zoster Immunoglobulin-VF 200IU Human Zoster Immunoglobulin	200	685	305	0.3	0.1	11.92	1,192
CMV Immunoglobulin-VF 1.5M U Human Cytomegalovirus Immunoglobulin	420	1,438	641	2.9	1.3	1.17	117
Tetanus Immunoglobulin-VF (IV use) 4000IU Human Tetanus Immunoglobulin	200	685	305	4.2	1.9	0.82	82
Tetanus Immunoglobulin-VF (IM use) 250IU Human Tetanus Immunoglobulin	420	1,438	641	0.3	0.1	11.82	1,182

References:

1. CSL Biotherapies data on file, Number of donations to make plasma products, 25/08/10.
2. CSL Biotherapies data on file, Toll Product Yields datasheet, Document number: DSH-022, edition 29.

Before prescribing, please review the approved Product Information available on request from CSL Biotherapies

PBS Information: These products are not listed on the PBS. These products are funded under arrangements implemented by the National Blood Authority. Please refer to the National Blood Authority for details.

The Medicines Australia Code of Conduct defines standards for the content of materials produced, and the conduct of promotional activities undertaken, by pharmaceutical companies within Australia. As a member of Medicines Australia, CSL Biotherapies willingly complies with the Medicines Australia Code of Conduct (www.medicinesaustralia.com.au).

CSL Limited, 189 - 209 Camp Road, Broadmeadows, Victoria, 3047, Australia. ABN: 99 051 588 348
For Medical/Technical Inquiries: Ph: 1800 642 865, For Customer Service Inquiries: Ph: 1800 063 892
E-mail: customerservice.plasmatherapies@csl.com.au, Internet: www.csl.com.au
© Registered trade mark of CSL Limited.

or
Australian Red Cross Blood Service, ABN: 50 169 561 394. Contact the local Transfusion Medicine Specialist in your capital city.
Email: clinicalinfo@redcrossblood.org.au, Internet: www.transfusion.com.au